Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Australian Pharmaceutical Industries Ltd (ASX:API)

Health Care Equipment & Services

Australian Pharmaceutical Industries Ltd (ASX:API) share price

share price: (end of day)

Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
Range: 1 mth | 3 mths | 6 mths | 1 yr | 2 yrs | 5 yrs | 10 yrs

On this page:

Australian Pharmaceutical Industries Ltd (ASX:API) business model

Australian Pharmaceutical Industries Ltd (ASX:API) is the pharmacy company behind Priceline, ClearSkincare, Soul Pattinson Chemist and much more. The Melbourne-based company is more than 100 years old and operates more than 500 chemists and hundreds more are included in its member network. API is part-owned by Washington H. Soul Pattinson (ASX: SOL).

6-month share price return (price only)

Australian Pharmaceutical Industries Ltd (ASX:API) dividends & profit

Earnings per share:

Dividends per share:

Rask Australia’s expert analysts have just released 11 stock & ETF positions they’d buy right now as part of a $10,000 hypothetical portfolio.

This report comes with the exact ticker codes, how much the analysts would invest and a detailed over the company and why we like it. Plus a 60-min podcast! Simply enter your email address and we’ll send you the report.

Today's Australian Pharmaceutical Industries Ltd (ASX:API) share price analysis & news

Rask Analyst’s $10,000 Hypothetical Portfolio 

Rask Australia’s expert analysts have just released 11 stock & ETF positions they’d buy right now as part of a $10,000 hypothetical portfolio. 

Completely free, this report comes with the exact ticker codes, how much the analysts would invest and a detailed over the company and why we like it. Plus a 60-min podcast! 

Simply enter your email address and we’ll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.